Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from CV Sciences ( (CVSI) ).
On August 13, 2025, CV Sciences announced its financial results for the second quarter of 2025, reporting a revenue of $3.6 million, a decrease from the previous year due to lower sales volume influenced by state regulatory pressures. Despite the revenue decline, the company achieved its highest gross margin since 2019 at 50.9% and reported its first positive adjusted EBITDA since 2019. The company is focusing on organic growth through new product development and mergers and acquisitions to improve profitability and shareholder value.
Spark’s Take on CVSI Stock
According to Spark, TipRanks’ AI Analyst, CVSI is a Neutral.
CV Sciences faces significant financial challenges, with declining revenues and negative profit margins being the most critical issues. Technical analysis provides a mixed outlook, while valuation concerns due to a negative P/E ratio further weigh down the score. The earnings call offers some optimism with strategic initiatives, but the overall outlook remains cautious.
To see Spark’s full report on CVSI stock, click here.
More about CV Sciences
CV Sciences, Inc. is a consumer wellness company specializing in nutraceuticals and plant-based foods, with a focus on hemp extracts and other science-backed natural ingredients. Their products, including the +PlusCBD brand, are sold through various channels and are recognized as top-selling in the natural products market. The company also offers cannabinoid-free supplements and plant-based food products, with operations in the U.S. and Europe.
Average Trading Volume: 226,987
Technical Sentiment Signal: Sell
Current Market Cap: $7.07M
See more insights into CVSI stock on TipRanks’ Stock Analysis page.